Cryoport to provide cryogenic logistics solutions to support personalized medicine efforts of CaRE Arthritis

Jun 17 2015

Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that the Company is the preferred cryogenic logistics provider to CaRE Arthritis ("CaRE").

Cryoport's comprehensive cryogenic logistics solutions will support CaRE Arthritis and their efforts in the development of personalized care options for arthritis. Cryoport's validated solutions provide integrity for temperature sensitive shipments supporting patient access for CaRE Arthritis research and development efforts. Cryoport offers a global network for greater safety and speed of the delivery.

CaRE Arthritis, based in Alberta, Canada, is an academic research organization that supports research and education for arthritis to patients and medical professionals, with an emphasis on the growing field of personalized medicine. The people of CaRE specialize in the development and application of biomarkers and medical imaging to further the advancement of the understanding of the disease. Biomarkers can play a critical role in identifying the severity of arthritic patients as well as their response to treatment.

Dr. Walter Maksymowych, Chief Medical Officer of CaRE Arthritis, stated, "The development and application of new imaging and biomarker technologies is an essential step to bringing the concept of personalized medicine to reality in the day-to-day management of arthritis. With the support of Cryoport's cold chain logistics, we are working tirelessly to better understand and efficiently treat the disease."

Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "We look forward to working with CaRE Arthritis to help them advance their research efforts. We offer comprehensive as well as best-in-class cryogenic solutions to an industry that needs reliability in order to accelerate forward. Cryoport is being recognized as a critical partner to the research community from a wide range of organizations."

SOURCE Cryoport, Inc.